August 2025 in “Dermatology and Therapy” This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.
May 2025 in “Acta Dermato Venereologica” This study found that individuals with hospital-treated alopecia areata in Denmark had increased standardized incidence rates of serious infections, herpes zoster infections, lymphoma, cardiovascular events, and death compared to the age- and sex-matched general population.
48 citations
,
January 2024 in “Immune Network” This review highlights recent insights into how IL-15 influences T cell responses and contributes to immunopathogenesis in various diseases, suggesting its crucial role in TCR-independent activation and potential in optimizing therapeutic strategies.
1 citations
,
October 2023 in “Dermatology and therapy” This review concluded that baricitinib and other oral JAK inhibitors have the most robust evidence supporting their use in treating severe alopecia areata in adults, compared to other less-evaluated treatments.
1 citations
,
June 2023 in “Dermatology and therapy” This study found that patients with alopecia areata had a higher incidence rate of herpes simplex infection compared to matched individuals without the condition.
40 citations
,
June 2021 in “Clinical, cosmetic and investigational dermatology” This review explores the efficacy and outcomes of using JAK inhibitors for treating alopecia areata, noting advancements in understanding the disease's pathomechanisms and suggesting that JAK inhibitors may offer targeted therapeutic benefits by blocking specific inflammatory pathways involved in this chronic condition.
134 citations
,
July 2020 in “Experimental dermatology” This review discusses immune privilege in anagen hair follicles and its collapse in alopecia areata, emphasizing the importance of restoring this function for effective management and disease relapse prevention.
9 citations
,
June 2018 in “Scientific Reports” This study reported that patients with alopecia areata or alopecia totalis/universalis have a slightly increased overall cancer risk compared to controls, with specific increases in thyroid, bladder, and prostate cancers depending on the alopecia type.
15 citations
,
March 2018 in “Cancer Medicine” This study found that alopecia areata patients had a slightly decreased overall cancer risk, with significantly lower risks for some cancers but higher risks for lymphoma, breast, kidney, and urinary bladder cancers.
56 citations
,
October 2016 in “Journal of dermatological science” This review explores multidisciplinary advances in understanding alopecia areata, including epidemiology, pathogenesis, and innovative treatments, but reports no new research results.